Last kr3.90 SEK
Change Today -0.10 / -2.50%
Volume 1.6K
GENO On Other Exchanges
Symbol
Exchange
Stockholm
As of 12:00 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

genovis ab (GENO) Snapshot

Open
kr3.90
Previous Close
kr4.00
Day High
kr3.90
Day Low
kr3.90
52 Week High
10/30/13 - kr5.92
52 Week Low
07/25/13 - kr3.32
Market Cap
88.3M
Average Volume 10 Days
3.2K
EPS TTM
kr-0.95
Shares Outstanding
21.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENOVIS AB (GENO)

Related News

No related news articles were found.

genovis ab (GENO) Related Businessweek News

No Related Businessweek News Found

genovis ab (GENO) Details

Genovis AB (publ) develops, produces, and markets technologies in the development of treatment methods and diagnostics for the medical device and pharmaceutical industries. It develops and sells enzymes in various product formats that facilitate development and quality control of biological drugs. The company’s products comprise FabRICATOR, an enzyme with proteolytic activity in hinge regions of IgG; FragIT, a FabRICATOR enzyme immobilized on agarose allowing for antibody subunit fragmentation without contaminating the final preparation with FabRICATOR enzyme; and FragIT kit that creates and isolates F(ab')2 and Fc fragments from IgG. It also offers FabULOUS, an enzyme that digests antibodies from various species and subclasses in the upper hinge region; and GlycINATOR, an endoglycosidase for minimizing side effects in various immunoassays caused by complement binding or cross-reactivity. In addition, the company provides IgGZERO, a recombinantely modified Endoglycosidase S from streptococcus pyogenes; and DeGlycIT, which is an IgGZERO (EndoS) enzyme that allows for removal of N-linked glycans associated to the Fc domain of IgG. Further, it develops a series of nanostructures for use as contrast agents in preclinical imaging. The company operates in Nordic region, rest of Europe, and the United States. Genovis AB (publ) was founded in 1999 and is based in Lund, Sweden.

15 Employees
Last Reported Date: 05/19/14
Founded in 1999

genovis ab (GENO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

genovis ab (GENO) Key Developments

Genovis AB Reports Consolidated and Company Earnings Results for the First Quarter Ended March 31, 2014

Genovis AB reported consolidated and company earnings results for the first quarter ended March 31, 2014. For the period, on consolidated basis, the company’s net sales were SEK 1,984,000 against SEK 1,906,000 a year ago. Operating loss before depreciation, amortization and impairment was SEK 3,604,000 against SEK 3,737,000 a year ago. Operating loss was SEK 3,878,000 against SEK 3,957,000 a year ago. Loss attributable to shareholders in company was SEK 3,838,000 against SEK 3,946,000 a year ago. Basic and diluted loss per share was SEK 0.19 against SEK 0.33 a year ago. Cash used in operating activities was SEK 6,213,000 against SEK 4,429,000 a year ago. Capital expenditure during the period totaled SEK 1,266,000 of which SEK 823,000 is attributable to property, plant, and equipment, primarily laboratory equipment and computers, and SEK 443,000 is attributable to investments in intangible fixed assets. For the period, the company’s operating income was SEK 2,751,000 against SEK 2,839,000 a year ago. Operating loss was SEK 3,874,000 against SEK 2,903,000 a year ago. Loss before tax was SEK 3,834,000 against SEK 4,003,000 a year ago. Loss for the period was SEK 3,834,000 against SEK 4,003,000 a year ago. Cash used in operating activities was SEK 4,820,000 against SEK 3,163,000 a year ago.

Genovis AB (publ) Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 2013

Genovis AB (publ) announced unaudited consolidated earnings results for the fourth quarter and year ended December 2013. For the quarter, on consolidated basis, the company's net sales were SEK 2.1 million compared with SEK 2.0 million a year ago. Operating loss was SEK 5.4 million compared with SEK 8.5 million a year ago. Loss attributable to shareholders in the company was SEK 5.3 million or SEK 0.34 per basic and diluted share compared with SEK 8.3 million or SEK 0.70 per basic and diluted share a year ago. Cash flow used in operating activities was SEK 1.5 million compared with SEK 3.9 million a year ago. Capital expenditure during the quarter totaled SEK 0.91 million compared with SEK 0.28 million a year ago. Operating loss before depreciation, amortization and impairment was SEK 5.2 million compared with SEK 4.3 million a year ago. For the year, on consolidated basis, the company's net sales were SEK 8.9 million compared with SEK 6.1 million a year ago. The increase was mainly due to the increased number of customers and the increased order value per customer. Operating loss was SEK 15.99 million compared with SEK 20.2 million a year ago. Loss attributable to shareholders in the company was SEK 15.85 million or SEK 1.10 per basic and diluted share compared with SEK 19.9 million or SEK 2.04 per basic and diluted share a year ago. Cash flow used in operating activities was SEK 12.5 million compared with SEK 14.8 million a year ago. Capital expenditure during the period totaled SEK 2.4 million compared with SEK 1.32 million a year ago. Operating loss before depreciation, amortization and impairment was SEK 14.9 million compared with SEK 14.98 million a year ago. For the quarter, on parent basis, the company's net sales were SEK 3.1 million compared with SEK 2.5 million a year ago. Operating loss was SEK 4.2 million compared with SEK 5.3 million a year ago. Loss before taxes was SEK 5.3 million compared with SEK 8.96 million a year ago. Loss for the period was SEK 5.3 million compared with SEK 8.6 million a year ago. Cash flow used in operating activities was SEK 0.4 million compared with SEK 3.6 million a year ago. For the year, on parent basis, the company's net sales were SEK 13.3 million compared with SEK 7.1 million a year ago. Operating loss was SEK 11.0 million compared with SEK 16.1 million a year ago. Loss before taxes was SEK 15.7 million compared with SEK 20.2 million a year ago. Loss for the period was SEK 15.7 million compared with SEK 19.8 million a year ago. Cash flow used in operating activities was SEK 8.2 million compared with SEK 13.9 million a year ago.

Genovis AB (publ), Annual General Meeting, May 20, 2014

Genovis AB (publ), Annual General Meeting, May 20, 2014. Location: Scheelevägen 2.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GENO:SS kr3.90 SEK -0.10

GENO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $118.61 USD +0.11
View Industry Companies
 

Industry Analysis

GENO

Industry Average

Valuation GENO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.4x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENOVIS AB, please visit www.genovis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.